IL317957A - Pyrido[4,3-d]pyrimidine compounds - Google Patents

Pyrido[4,3-d]pyrimidine compounds

Info

Publication number
IL317957A
IL317957A IL317957A IL31795724A IL317957A IL 317957 A IL317957 A IL 317957A IL 317957 A IL317957 A IL 317957A IL 31795724 A IL31795724 A IL 31795724A IL 317957 A IL317957 A IL 317957A
Authority
IL
Israel
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
alkyl
alkylene
Prior art date
Application number
IL317957A
Other languages
Hebrew (he)
Inventor
Jacob Cole Deforest
Asako Nagata
Simon Paul Planken
Jillian Elyse Spangler
Scott Channing Sutton
John Howard Tatlock
Original Assignee
Pfizer
Jacob Cole Deforest
Asako Nagata
Simon Paul Planken
Jillian Elyse Spangler
Scott Channing Sutton
John Howard Tatlock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Jacob Cole Deforest, Asako Nagata, Simon Paul Planken, Jillian Elyse Spangler, Scott Channing Sutton, John Howard Tatlock filed Critical Pfizer
Publication of IL317957A publication Critical patent/IL317957A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (25)

- 104 - PC072879A CLAIMS We claim:
1. A compound of Formula (V): (V) or a pharmaceutically acceptable salt thereof, wherein: R is selected from the group consisting of: ; R is C alkyl, C alkyl, -(C alkylene)-OH, or -(C alkylene)-OH; R is selected from the group consisting of: - 105 - ; R is Cl or F; R is -(C alkylene)-OH, or C alkyl, wherein R and R are optionally taken together to form a 7-membered heterocycloalkyl comprising one heteroatom O; R represents one or two substituents selected from the group consisting of H, -OH, halogen, -(C-C alkylene)-OH, -CN, -(C-C alkylene)-CN, C‑C alkyl, C‑C cycloalkyl, C‑C fluoroalkyl, C‑C fluorocycloalkyl, and C‑C alkoxy; L is a linker comprising one, two or three members independently selected from the group consisting of -O-, -S-, -NR-, and -CRR-; R, R, and R are each independently H or C‑C alkyl; X is O, N, or S; and l is 1 or 2.
2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of:
3. . 3. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein R is: . 20 - 106 -
4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R is C alkyl, and R is -(C alkylene)-OH.
5. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R is -(C alkylene)-OH, and R is C alkyl.
6. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein R and R are taken together to form a 7-membered heterocycloalkyl comprising one heteroatom O.
7. The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein R and R are taken together to form a 7-membered heterocycloalkyl comprising one heteroatom O.
8. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein Ris:
9. . 9. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein R is F.
10. The compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein X is O, l is 1.
11. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has Formula (VI): . - 107 - (VI)
12. The compound of claim 11, or a pharmaceutically acceptable salt thereof, wherein R is C alkyl, and R is -(C alkylene)-OH.
13. The compound of claim 11, or a pharmaceutically acceptable salt thereof, wherein R is -(C alkylene)-OH, and R is C alkyl.
14. The compound of claim 12, or a pharmaceutically acceptable salt thereof, wherein R and R are taken together to form a 7-membered heterocycloalkyl comprising one heteroatom O.
15. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein R and R are taken together to form a 7-membered heterocycloalkyl comprising one heteroatom O.
16. A compound of Formula (VII) (VII) or a pharmaceutically acceptable salt thereof, wherein R, R, R, and R are each independently H or C‑C alkyl.
17. The compound of claim 16, or a pharmaceutically acceptable salt thereof, wherein R, R, R, and R are each independently H or methyl.
18. The compound of claim 16 or 17, or a pharmaceutically acceptable salt thereof, wherein the compound is 25 - 108 -
19. . 19. A compound or a pharmaceutically acceptable salt thereof, selected from the group consisting of: and
20. . 20. A pharmaceutical composition comprising a compound of any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
21. A compound of any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, for use as a medicament. 15 - 109 -
22. A compound of any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer.
23. A compound for use in the treatment of cancer according to claim 22, wherein the cancer is small cell lung cancer (NSCLC), pancreatic cancer, or colorectal cancer.
24. A pharmaceutical combination comprising a compound of any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, and at least one additional therapeutic agent or a pharmaceutically acceptable salt thereof.
25. A pharmaceutical composition comprising the pharmaceutical combination of claim 24 and at least one excipient.
IL317957A 2022-07-05 2023-06-30 Pyrido[4,3-d]pyrimidine compounds IL317957A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263358324P 2022-07-05 2022-07-05
US202263394338P 2022-08-02 2022-08-02
US202263414939P 2022-10-11 2022-10-11
US202363502931P 2023-05-18 2023-05-18
PCT/IB2023/056844 WO2024009191A1 (en) 2022-07-05 2023-06-30 Pyrido[4,3-d]pyrimidine compounds

Publications (1)

Publication Number Publication Date
IL317957A true IL317957A (en) 2025-02-01

Family

ID=87426656

Family Applications (1)

Application Number Title Priority Date Filing Date
IL317957A IL317957A (en) 2022-07-05 2023-06-30 Pyrido[4,3-d]pyrimidine compounds

Country Status (17)

Country Link
EP (1) EP4551296A1 (en)
JP (1) JP2025525406A (en)
KR (1) KR20250029954A (en)
CN (1) CN119585286A (en)
AU (1) AU2023302139A1 (en)
CA (1) CA3261000A1 (en)
CL (1) CL2024003699A1 (en)
CO (1) CO2024016875A2 (en)
CR (1) CR20240556A (en)
DO (1) DOP2024000275A (en)
IL (1) IL317957A (en)
MA (1) MA71388A (en)
MX (1) MX2024015001A (en)
PE (1) PE20250259A1 (en)
PY (1) PY2352053A (en)
TW (2) TWI869913B (en)
WO (1) WO2024009191A1 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (en) 2018-04-04 2021-01-12 Arvinas Operations, Inc. PROTEOLYSIS MODULATORS AND ASSOCIATED METHODS OF USE
MD4051678T2 (en) 2019-10-28 2026-07-31 Merck Sharp & Dohme Llc Small molecule inhibitors of kras g12c mutant
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. Novel phenol compound or salt thereof
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
WO2022109487A1 (en) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
US20260200925A1 (en) * 2021-11-24 2026-07-16 Merck Sharp & Dohme Llc Small molecule inhibitors of kras mutated proteins
WO2023172737A1 (en) 2022-03-11 2023-09-14 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
AU2023320565A1 (en) 2022-08-05 2025-01-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2024032703A1 (en) * 2022-08-11 2024-02-15 Beigene, Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
AU2023321005A1 (en) * 2022-08-12 2025-03-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tricyclic compounds and medical use thereof
TW202434606A (en) * 2022-11-17 2024-09-01 大陸商江蘇恆瑞醫藥股份有限公司 Fused tricyclic compounds, their preparation methods, and their applications in medicine
PE20260006A1 (en) 2023-01-26 2026-01-06 Arvinas Operations Inc Cereblon-based KRAS degraders and related uses
WO2024178304A1 (en) * 2023-02-24 2024-08-29 Alterome Therapeutics, Inc. Kras modulators
CN121487738A (en) 2023-03-30 2026-02-06 锐新医药公司 Compositions for inducing RAS GTP hydrolysis and their uses
CR20250413A (en) * 2023-04-05 2025-11-06 Pfizer Pyrido[4,3–d]pyrimidine compounds
WO2024218686A1 (en) * 2023-04-20 2024-10-24 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
KR20260019479A (en) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Combination therapy for RAS-related diseases or disorders
CN121194980A (en) * 2023-05-16 2025-12-23 和记黄埔医药(上海)有限公司 Tricyclic compounds and their uses
EP4724445A1 (en) 2023-06-06 2026-04-15 Kumquat Biosciences Inc. Substituted heterocycles and uses thereof
EP4735451A1 (en) 2023-06-30 2026-05-06 Kumquat Biosciences Inc. Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
WO2025006967A1 (en) 2023-06-30 2025-01-02 Bristol-Myers Squibb Company Kras inhibitors
CN121889155A (en) 2023-08-07 2026-04-17 锐新医药公司 RMC-6291 for the treatment of RAS protein-related diseases or disorders
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR20260096846A (en) 2023-10-20 2026-06-24 머크 샤프 앤드 돔 엘엘씨 Small molecule inhibitors of KRAS protein
AU2024404270A1 (en) * 2023-12-19 2026-07-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Fused tricyclic compound and medical use thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202608896A (en) * 2024-04-30 2026-03-01 大陸商和記黃埔醫藥(上海)有限公司 Antibody-drug conjugate and use thereof
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026035945A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
TW202615038A (en) 2024-08-07 2026-04-16 美商太斯萊特醫藥美國有限責任公司 Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026064520A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
WO2026064527A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors
CN119874616B (en) * 2025-03-28 2025-05-30 四川美域高生物医药科技有限公司 An organic intermediate and its preparation method and application

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
SI2242771T1 (en) 2007-12-14 2013-09-30 Bristol-Myers Squibb Company Binding molecules to the human ox40 receptor
SA112330278B1 (en) 2011-02-18 2015-10-09 ستيم سينتركس، انك. Novel modulators and methods of use
EP2760857A1 (en) 2011-09-27 2014-08-06 F.Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
EP2780039B9 (en) 2011-11-17 2018-04-18 Pfizer Inc Cytotoxic peptides and antibody drug conjugates thereof
MX2016017393A (en) 2014-07-01 2017-09-05 Pfizer Bispecific heterodimeric diabodies and uses thereof.
HUE057285T2 (en) 2015-04-13 2022-04-28 Pfizer Therapeutic antibodies and their uses
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
SG10201900628RA (en) 2016-04-07 2019-02-27 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
US11589667B2 (en) 2016-11-16 2023-02-28 Wink Robotics Deformable end effectors for cosmetic robotics
WO2018206539A1 (en) * 2017-05-11 2018-11-15 Astrazeneca Ab Heteroaryl compounds that inhibit g12c mutant ras proteins
CN111148762A (en) 2017-05-31 2020-05-12 斯特库伯株式会社 Antibodies and molecules that immunospecifically bind to BTN1a1 and therapeutic uses thereof
JP7234142B2 (en) 2017-06-02 2023-03-07 ファイザー・インク Antibodies specific for FLT3 and uses thereof
MA49772A (en) 2017-08-04 2021-04-21 Merck Sharp & Dohme STING THIOPHENE BENZO [B] AGONISTS FOR CANCER TREATMENT
EP3964516A4 (en) * 2019-04-28 2023-01-11 Genfleet Therapeutics (Shanghai) Inc. OXAAZAQUINAZOLINE-7(8H)-KETONE COMPOUND, METHOD FOR PREPARATION AND PHARMACEUTICAL APPLICATION
CN114615981B (en) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 KRAS G12D inhibitors
CN113980032B (en) * 2020-07-27 2023-06-16 江苏恒瑞医药股份有限公司 Fused tetracyclic derivative, preparation method thereof and application thereof in medicines
EP4262807A4 (en) * 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azaquinazoline pan-kras inhibitors
CN117083281A (en) * 2021-03-24 2023-11-17 南京明德新药研发有限公司 Pyrimidoheterocyclic compounds and their applications
TW202315626A (en) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 Pyrimidine-fused cyclic compound and preparation method and use thereof
CN118019746A (en) * 2021-09-27 2024-05-10 北京加科思新药研发有限公司 Polycyclic fused ring derivatives and uses thereof

Also Published As

Publication number Publication date
TW202409047A (en) 2024-03-01
CA3261000A1 (en) 2024-01-11
AU2023302139A1 (en) 2024-12-19
TWI869913B (en) 2025-01-11
MX2024015001A (en) 2025-01-09
CO2024016875A2 (en) 2024-12-19
PY2352053A (en) 2025-03-06
TW202513571A (en) 2025-04-01
KR20250029954A (en) 2025-03-05
EP4551296A1 (en) 2025-05-14
CL2024003699A1 (en) 2025-04-11
JP2025525406A (en) 2025-08-05
MA71388A (en) 2025-04-30
CR20240556A (en) 2025-01-29
CN119585286A (en) 2025-03-07
DOP2024000275A (en) 2025-01-31
PE20250259A1 (en) 2025-01-29
WO2024009191A1 (en) 2024-01-11

Similar Documents

Publication Publication Date Title
TWI869913B (en) PYRIDO[4,3-d]PYRIMIDINE COMPOUNDS
CA2959688C (en) Quinolone compounds and their use to treat diseases related to hypoxia inducible factor and/or erythropoietin
EP2854796B1 (en) Combinations of a vascular disrupting agent and a hypoxia-targeting agent for use in the treatment of cancer
EP4004002B1 (en) Macrocyclic compounds as sting agonists and methods and uses thereof
CN103797001B (en) Benzothiazole compounds and their pharmaceutical applications
AU2018308871A1 (en) Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer
JP2016172739A5 (en)
EA023646B1 (en) SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-c]QUINAZOLINE SALTS
JPH02212435A (en) Method for treating endotoxin shock in mammalia
KR940005566A (en) Quinoline compounds
JP2021102643A5 (en)
WO2013103738A1 (en) Napthalene acetic acid derivatives against hiv infection
JP2015500885A5 (en)
TW202038947A (en) Helicase primase inhibitors for treating cancer in a combination therapy with oncolytic viruses
JP2008500366A5 (en)
JP2004502732A5 (en)
WO2018133661A1 (en) Novel boric acid derivative and pharmaceutical composition using same
KR20240004657A (en) Use of medicine in the treatment of neoplastic diseases
JP2018529737A5 (en)
KR20210070978A (en) Compounds and uses thereof
CN104557939A (en) Hydrochloride of pyrrolo-pyrazine compound and application of hydrochloride
US9738613B2 (en) Substituted 1,2,3-triazoles as antitumor agents
ES2928666T3 (en) Pyridinethiones, their pharmaceutical compositions and their therapeutic use for the treatment of proliferative, inflammatory, neurodegenerative or immune-mediated diseases
RU2441021C2 (en) Lysobactinamides
US20150376216A1 (en) Sugar-analog phosphorus-containing heterocycles having an anti-metastatic activity